Thứ 2 - Thứ 7 (09am - 10pm)

+84-24-6297-7875

BoruzaThành phần sản phẩm

  

 

Tenofovir disoproxil fumarat 300 mg

BoruzaChi tiết sản phẩm

Registration number: QLDB-504-15 Packing Box: 3 blisters x 10 tablets
Standard: in-house
Expiry date: 36 months
Manufacturing company: Pharmaceutical and Biomedical Co., Ltd
Dosage form: Long film coated tablets.
Ingredients: Tenofovir disoproxil fumarate 300 mg
Point:
- The drug is used in combination with other antiretroviral drugs (not used alone) in the treatment of HIV - type 1 infection (in adults).
- Used in combination with other antiretroviral agents in the prevention of HIV infection after exposure to the disease in individuals at risk of viral infection.
- Used in the treatment of chronic hepatitis B in adults, tenofovir is active against lamivudine-resistant mutant HBV.
Contraindications: Patients with hypersensitivity to tenofovir disoproxil fumarate or any component of the drug.

Side effects:

- The most common effects when using tenofovir disoproxil fumarate are mild effects on the gastrointestinal tract, especially diarrhea, vomiting and nausea, abdominal pain, flatulence, dyspepsia, loss of appetite.

- Serum amylase levels may be elevated and pancreatitis may occur.

- Hypophosphatemia is also common.

Skin rash may also occur.

Other common side effects include peripheral neuropathy, headache, dizziness, insomnia, depression, weakness, sweating, and muscle pain.

- Increased liver enzymes, increased blood triglyceride levels, hyperglycemia and neutrophil deficiency.

Renal failure, acute renal failure and proximal tubular effects, including Fanconi's syndrome

Lactic acidosis, often associated with severe hepatomegaly and steatosis, is common with treatment with nucleoside reverse transcriptase inhibitors.

Pregnant and lactating women:

Pregnant:

There is no information on the use of tenofovir disoproxil fumarate during pregnancy. Tenofovir disoproxil fumarate should only be used when the demonstrated benefit outweighs the risk to the fetus.

However, because of the unknown increased risk of conception, the use of tenofovir disoproxil fumarate in women of reproductive age should be accompanied by effective methods of contraception.

Women who are breastfeeding:

There is no information on the excretion of tenofovir disoproxil fumarate in human milk.

Therefore, tenofovir should not be used in nursing women. As a general recommendation, women with HIV should not breastfeed to avoid transmitting HIV to their babies.

Effects on machine operators and motorcyclists:

No studies have shown that the drug affects the ability to drive and use machines. However, patients should be informed of the potential for dizziness during treatment with tenofovir disoproxil fumarate.

Dosage:

Tenofovir 300 mg is administered orally once daily, unaffected by meals.

Adult:

Treatment of HIV infection:

-1 tablet x 1 time/day, in combination with other antiretroviral drugs.

- Prophylaxis of HIV infection after occupational exposure: 1 tablet x 1 time/day in combination with other antiretroviral drugs (usually in combination with lamivudine or emtricitabine).

Prophylaxis should begin as soon as possible after occupational exposure (preferably within hours rather than days) and continue for the next 4 weeks if tolerated.

- Prophylaxis of non-occupational HIV infection: 1 tablet x 1 time/day in combination with at least 2 other antiretroviral drugs.

Prophylaxis should begin as soon as possible after non-occupational exposure (preferably within 72 hours) and continue for 28 days.

Treatment of chronic hepatitis B virus:

The recommended dose is 1 tablet once daily for more than 48 weeks.

Patients with renal failure:

The dose of tenofovir disoproxil fumarate should be reduced by adjusting the dosing interval in patients with renal impairment based on the patient's creatinine clearance (CC):

* CC 50 ml/min or greater: usual dose once daily.

* CC 30 to 49 ml/min: every 48 hours.

* CC 10 to 29 ml/min: every 72 to 96 hours.

* Patients on hemodialysis: take each dose 7 days apart or 12 hours after dialysis.

Since the safety and efficacy of these doses have not been clinically evaluated, clinical response to therapy and renal function should be closely monitored.

Patients with liver failure:

For patients with impaired liver function, no dose adjustment is necessary.

Đăng ký tư vấn

Để giúp quá trình xử lý được tốt hơn, mời anh/chị "ĐIỀN THÊM THÔNG TIN" vào các mục bên dưới.

Dược Phẩm Tùng LinhSản phẩm liên quan

Boruza

Tình trạng: Sẵn có

Giới thiệu tổng quát

Registration number: QLDB-504-15 Packing Box: 3 blisters x 10 tablets
Standard: in-house
Expiry date: 36 months
Manufacturing company: Pharmaceutical and Biomedical Co., Ltd
Dosage form: Long film coated tablets.
Ingredients: Tenofovir disoproxil fumarate 300 mg
Point:
- The drug is used in combination with other antiretroviral drugs (not used alone) in the treatment of HIV - type 1 infection (in adults).
- Used in combination with other antiretroviral agents in the prevention of HIV infection after exposure to the disease in individuals at risk of viral infection.
- Used in the treatment of chronic hepatitis B in adults, tenofovir is active against lamivudine-resistant mutant HBV.
Contraindications: Patients with hypersensitivity to tenofovir disoproxil fumarate or any component of the drug.

Side effects:

- The most common effects when using tenofovir disoproxil fumarate are mild effects on the gastrointestinal tract, especially diarrhea, vomiting and nausea, abdominal pain, flatulence, dyspepsia, loss of appetite.

- Serum amylase levels may be elevated and pancreatitis may occur.

- Hypophosphatemia is also common.

Skin rash may also occur.

Other common side effects include peripheral neuropathy, headache, dizziness, insomnia, depression, weakness, sweating, and muscle pain.

- Increased liver enzymes, increased blood triglyceride levels, hyperglycemia and neutrophil deficiency.

Renal failure, acute renal failure and proximal tubular effects, including Fanconi's syndrome

Lactic acidosis, often associated with severe hepatomegaly and steatosis, is common with treatment with nucleoside reverse transcriptase inhibitors.

Pregnant and lactating women:

Pregnant:

There is no information on the use of tenofovir disoproxil fumarate during pregnancy. Tenofovir disoproxil fumarate should only be used when the demonstrated benefit outweighs the risk to the fetus.

However, because of the unknown increased risk of conception, the use of tenofovir disoproxil fumarate in women of reproductive age should be accompanied by effective methods of contraception.

Women who are breastfeeding:

There is no information on the excretion of tenofovir disoproxil fumarate in human milk.

Therefore, tenofovir should not be used in nursing women. As a general recommendation, women with HIV should not breastfeed to avoid transmitting HIV to their babies.

Effects on machine operators and motorcyclists:

No studies have shown that the drug affects the ability to drive and use machines. However, patients should be informed of the potential for dizziness during treatment with tenofovir disoproxil fumarate.

Dosage:

Tenofovir 300 mg is administered orally once daily, unaffected by meals.

Adult:

Treatment of HIV infection:

-1 tablet x 1 time/day, in combination with other antiretroviral drugs.

- Prophylaxis of HIV infection after occupational exposure: 1 tablet x 1 time/day in combination with other antiretroviral drugs (usually in combination with lamivudine or emtricitabine).

Prophylaxis should begin as soon as possible after occupational exposure (preferably within hours rather than days) and continue for the next 4 weeks if tolerated.

- Prophylaxis of non-occupational HIV infection: 1 tablet x 1 time/day in combination with at least 2 other antiretroviral drugs.

Prophylaxis should begin as soon as possible after non-occupational exposure (preferably within 72 hours) and continue for 28 days.

Treatment of chronic hepatitis B virus:

The recommended dose is 1 tablet once daily for more than 48 weeks.

Patients with renal failure:

The dose of tenofovir disoproxil fumarate should be reduced by adjusting the dosing interval in patients with renal impairment based on the patient's creatinine clearance (CC):

* CC 50 ml/min or greater: usual dose once daily.

* CC 30 to 49 ml/min: every 48 hours.

* CC 10 to 29 ml/min: every 72 to 96 hours.

* Patients on hemodialysis: take each dose 7 days apart or 12 hours after dialysis.

Since the safety and efficacy of these doses have not been clinically evaluated, clinical response to therapy and renal function should be closely monitored.

Patients with liver failure:

For patients with impaired liver function, no dose adjustment is necessary.